Furthermore, subgroup analysis indicated that PPP4C is particularly valuable for predicting the prognosis of high-risk DLBCL patients (IPI > 2, ECOG > 2, stage III–IV, and non-GCL). Here, PPP4C is linked to Berardinelli-Seip congenital lipodystrophy.